Endometrial undifferentiated carcinoma
diseaseOn this page
Also known as undifferentiated endometrial carcinoma
Summary
Endometrial undifferentiated carcinoma (MONDO:0006199) is a cancer and 17 clinical trials. Top therapeutic interventions include carboplatin, capivasertib, and copanlisib. A subtype of endometrial carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 17
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | endometrial undifferentiated carcinoma |
| Mondo ID | MONDO:0006199 |
| EFO | EFO:1000242 |
| ICD-11 | 130578959 |
| NCIT | C40156 |
| UMLS | C1516865 |
| MedGen | 274013 |
| Anatomy (UBERON) | UBERON:0001295 |
| Is cancer (heuristic) | yes |
Also known as: endometrial undifferentiated carcinoma · undifferentiated endometrial carcinoma
Data availability: 3 cell lines.
Disease family
This is a subtype of endometrial carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine carcinoma › endometrial carcinoma › endometrial undifferentiated carcinoma
Related subtypes (6): uterine corpus endometrial carcinoma, endometrial transitional cell carcinoma, endometrium carcinoma in situ, endometrium adenocarcinoma, endometrial small cell carcinoma, endometrial squamous cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 17.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 8 |
| PHASE1 | 5 |
| PHASE3 | 2 |
| PHASE2/PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03914612 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer |
| NCT05256225 | PHASE3 | RECRUITING | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma |
| NCT02065687 | PHASE2/PHASE3 | UNKNOWN | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer |
| NCT03660826 | PHASE2 | ACTIVE_NOT_RECRUITING | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone |
| NCT04719273 | PHASE2 | ACTIVE_NOT_RECRUITING | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer |
| NCT05112601 | PHASE2 | RECRUITING | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma |
| NCT00492778 | PHASE2 | UNKNOWN | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer |
| NCT00888173 | PHASE2 | COMPLETED | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| NCT01225887 | PHASE2 | COMPLETED | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| NCT01642082 | PHASE2 | COMPLETED | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| NCT02728258 | PHASE2 | COMPLETED | Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer |
| NCT03120624 | PHASE1 | ACTIVE_NOT_RECRUITING | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer |
| NCT00575952 | PHASE1 | COMPLETED | Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer |
| NCT01440998 | PHASE1 | COMPLETED | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer |
| NCT01935973 | PHASE1 | COMPLETED | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| NCT02020707 | PHASE1 | COMPLETED | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers |
| NCT05390021 | Not specified | WITHDRAWN | PET/MRI in Endometrial Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CARBOPLATIN | 4 | 4 |
| CAPIVASERTIB | 4 | 1 |
| COPANLISIB | 4 | 1 |
| HYALURONIDASE (HUMAN RECOMBINANT) | 4 | 1 |
| METFORMIN | 4 | 1 |
| NINTEDANIB | 4 | 1 |
| PEMBROLIZUMAB | 4 | 1 |
| PERTUZUMAB | 4 | 1 |
| RUXOLITINIB | 4 | 1 |
| SODIUM PERTECHNETATE TC 99M | 4 | 1 |
| BRIVANIB ALANINATE | 3 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| DALANTERCEPT | 3 | 1 |
| ONAPRISTONE | 2 | 1 |
| UPROSERTIB | 2 | 1 |
| ZENIDOLOL | 2 | 1 |